N-methyl-N-pentyl-hydrazine | 20240-64-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-methyl-N-pentyl-hydrazine
• 英文别名: 1-Methyl-1-pentylhydrazine
• CAS: 20240-64-6
• 化学式: C₆H₁₆N₂
• 分子量: 116.206
• InChiKey: ODGQBTNDOGTTEM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  8
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-methyl-N-pentyl-hydrazine 、 3甲酰利福平霉素 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 3-[(methyl-pentyl-hydrazono)-methyl]-rifamycin
  参考文献：
  名称：

  Cricchio; Carniti; Cietto, Farmaco, Edizione Scientifica, 1975, vol. 30, # 9, p. 704 - 720

  摘要：

  DOI：

文献信息

• 2-aminoarylmethylamine solid support templated for preparation of highly functionalized heterocycle compounds
  申请人：——

  公开号：US20020032262A1

  公开（公告）日：2002-03-14

  A solid support template for the preparation of highly functionalized heterocycle compounds of the formula; 1

  一种固体支撑模板，用于制备公式为1的高度功能化杂环化合物。
• Nitrogen-containing bicyclic heteroaryl compounds and methods of use
  申请人：De Morin F. Frenel

  公开号：US20070185324A1

  公开（公告）日：2007-08-09

  The present invention comprises a new class of compounds capable of modulating Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have a general Formula I wherein R 1 is and A 1 , A 2 , A 3 , A 4 , X, Z, Z′, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.

  本发明涉及一种新的化合物类别，能够调节Raf激酶，因此有助于治疗由Raf激酶介导的疾病，包括黑色素瘤、肿瘤和其他与癌症相关的疾病。该化合物具有通用的I式，其中R1为，A1、A2、A3、A4、X、Z、Z'、R2、R3、R4、R5和R6在此被定义。本发明还包括制备本发明化合物的中间体和方法，以及用于治疗Raf激酶介导的疾病的制药组合物。
• NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS AND METHODS OF USE
  申请人：De Morin Frenel F.

  公开号：US20110251199A1

  公开（公告）日：2011-10-13

  The present invention comprises a new class of compounds capable of modulating Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have a general Formula I and A 1 , A 2 , A 3 , A 4 , X, Z, Z′, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.

  本发明涵盖了一种新的化合物类别，能够调节Raf激酶，因此可用于治疗Raf激酶介导的疾病，包括黑色素瘤、肿瘤和其他与癌症相关的疾病。该化合物具有一般的I式，其中A1、A2、A3、A4、X、Z、Z'、R1、R2、R3、R4、R5和R6在此定义。本发明还涵盖了制备该化合物的中间体和方法，以及用于治疗Raf激酶介导的疾病的制药组合物。
• LATENT CURING AGENTS, EPOXY RESIN COMPOSITIONS CONATING THE SAME, SEALING MATERIALS, AND ORGANIC EL DISPLAYS
  申请人：Mitsui Chemicals, Inc.

  公开号：EP2199313A1

  公开（公告）日：2010-06-23

  The invention aims to provide latent curing agents which exert high low-temperature curing properties when used together with ionically polymerizable compounds and which exhibit high storage stability at room temperature. Latent curing agents for ionically polymerizable compounds which agents each contain a hydroxyl-free amine imide compound having an N-N bond energy of 100 to 210 kJ/mol as determined by B3LYP functional theory method.

  本发明旨在提供与离子可聚合化合物一起使用时具有较高低温固化性能，并且在室温下具有较高储存稳定性的潜在固化剂。用于离子可聚合化合物的潜在固化剂，每种固化剂都含有一种无羟基胺亚胺化合物，根据 B3LYP 功能理论方法测定，其 N-N 键能量为 100 至 210 kJ/mol。
• Nintrogen-containing bicyclic heteroaryl compounds for the treatment of RAF protein kinase-mediated diseases
  申请人：Amgen Inc.

  公开号：EP2481729A1

  公开（公告）日：2012-08-01

  The present invention comprises a new class of compounds capable of modulating Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have a general Formula I wherein R1 is

  本发明包括一类能够调节 Raf 激酶的新型化合物，因此可用于治疗 Raf 激酶介导的疾病，包括黑色素瘤、肿瘤和其他癌症相关疾病。这些化合物具有通式 I 其中 R1 是